scholarly journals The Novel Use of Zwitterionic Bacterial Components and Polysaccharides in Immunotherapy of Cancer and Immunosuppressed Cancer Patients

10.5772/30540 ◽  
2012 ◽  
Author(s):  
A.S. Abdulamir ◽  
R.R. Hafidh ◽  
F. Abubaker
Keyword(s):  
Cancer Patients ◽  
The Novel ◽  
Immunotherapy Of Cancer

scholarly journals Associations between Statin/Omega3 Usage and MRI-Based Radiomics Signatures in Prostate Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 85
Author(s):  
Yu Shi ◽  
Ethan Wahle ◽  
Qian Du ◽  
Luke Krajewski ◽  
Xiaoying Liang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Bias Correction ◽  
Cross Validation ◽  
Prostate Cancer Risk ◽  
Tissue Level ◽  
Peripheral Region ◽  
The Novel ◽  
Omega 3 ◽  
Field Bias

Prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer deaths among American men. Statins and omega-3 are two medications recently found to correlate with prostate cancer risk and aggressiveness, but the observed associations are complex and controversial. We therefore explore the novel application of radiomics in studying statin and omega-3 usage in prostate cancer patients. On MRIs of 91 prostate cancer patients, two regions of interest (ROIs), the whole prostate and the peripheral region of the prostate, were manually segmented. From each ROI, 944 radiomic features were extracted after field bias correction and normalization. Heatmaps were generated to study the radiomic feature patterns against statin or omega-3 usage. Radiomics models were trained on selected features and evaluated with 500-round threefold cross-validation for each drug/ROI combination. On the 1500 validation datasets, the radiomics model achieved average AUCs of 0.70, 0.74, 0.78, and 0.72 for omega-3/prostate, omega-3/peripheral, statin/prostate, and statin/peripheral, respectively. As the first study to analyze radiomics in relation to statin and omega-3 uses in prostate cancer patients, our study preliminarily established the existence of imaging-identifiable tissue-level changes in the prostate and illustrated the potential usefulness of radiomics for further exploring these medications’ effects and mechanisms in prostate cancer.

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients

2002 ◽  
Vol 13 (8) ◽  
pp. 807-814 ◽  
Author(s):  
HJG Desirée van den Bongard ◽  
Dick Pluim ◽  
Hilde Rosing ◽  
Lianda Nan-Offeringa ◽  
Margaret Schot ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Pharmacokinetic Study ◽  
Anticancer Agent ◽  
The Novel ◽  
Excretion Balance

scholarly journals The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation

2020 ◽  
Vol 48 (7) ◽  
pp. 3816-3831 ◽  
Author(s):  
Tao Liu ◽  
Qinglv Wei ◽  
Jing Jin ◽  
Qingya Luo ◽  
Yi Liu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Protein Translation ◽  
Translation Initiation Factor ◽  
Initiation Factor ◽  
Rna Modification ◽  
Dependent Manner ◽  
The Novel ◽  
A Subunit

Abstract N 6-Methyladenosine (m6A) is the most abundant RNA modification in mammal mRNAs and increasing evidence suggests the key roles of m6A in human tumorigenesis. However, whether m6A, especially its ‘reader’ YTHDF1, targets a gene involving in protein translation and thus affects overall protein production in cancer cells is largely unexplored. Here, using multi-omics analysis for ovarian cancer, we identified a novel mechanism involving EIF3C, a subunit of the protein translation initiation factor EIF3, as the direct target of the YTHDF1. YTHDF1 augments the translation of EIF3C in an m6A-dependent manner by binding to m6A-modified EIF3C mRNA and concomitantly promotes the overall translational output, thereby facilitating tumorigenesis and metastasis of ovarian cancer. YTHDF1 is frequently amplified in ovarian cancer and up-regulation of YTHDF1 is associated with the adverse prognosis of ovarian cancer patients. Furthermore, the protein but not the RNA abundance of EIF3C is increased in ovarian cancer and positively correlates with the protein expression of YTHDF1 in ovarian cancer patients, suggesting modification of EIF3C mRNA is more relevant to its role in cancer. Collectively, we identify the novel YTHDF1-EIF3C axis critical for ovarian cancer progression which can serve as a target to develop therapeutics for cancer treatment.

scholarly journals Cancer Patients on Twitter: The Novel Communities on Social Media

2012 ◽  
Vol 23 ◽  
pp. xi109 ◽  
Author(s):  
H. Narimatsu ◽  
Y. Sugawara ◽  
A. Fukao
Keyword(s):  
Social Media ◽  
Cancer Patients ◽  
The Novel

scholarly journals Utilization of Intravenous (IV) Curcumin, Genistein, and Trastuzumab to Reduce HER2 receptors in Breast Cancer Patients

2021 ◽  
Vol 8 (4) ◽  
Author(s):  
Shreya Bhandari ◽  
Hasmitha Kamineni
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Kinase Inhibitors ◽  
The Novel ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Protein ◽  
Protein Receptors ◽  
Novel Method ◽  
Future Work

In recent decades, due to the increased growth, spread, and onset of cancer, interest has arisen in studying the methods that could be used to combat it. Breast cancer is the most prevalent form of cancer in the world. Due to the growing pervasiveness of this issue, a larger body of research is forming in the area of breast cancer with the intent to contain the spread of the potentially ravaging disease or diagnose it earlier. This research is intended to propose an alternative, possibly more efficient method to inhibit the chances of metastasis and continued prevalence of breast cancer in a patient. The related work discusses similar research being done and builds on it to incorporate the novel method being proposed while explaining the components of the proposed treatment in question. The proposed method aims to deplete HER2 protein receptors in breast cancer patients through the intravenous (IV) administration of the tyrosine kinase inhibitors (TKIs) curcumin and genistein, as well as trastuzumab, which is more commonly known under the brand name Herceptin. Depleting HER2 protein receptors can potentially cause the severity of HER2-positive breast cancer to decrease substantially, as well as reduce the probability of metastasis and recurrence, the rate of which is considerably higher in HER2-positive cases when compared to that of HER2-negative cases. The future work deals with alternate methods that could be explored with a similar intent as this research study and describes the potential implications of the study.

scholarly journals “Door to Treatment” Outcomes of Cancer Patients during the COVID-19 Pandemic

Chemotherapy ◽  
2020 ◽  
pp. 1-6
Author(s):  
Naziye Ak ◽  
Sezai Vatansever
Keyword(s):  
Cancer Patients ◽  
Treatment Time ◽  
Index Case ◽  
Neoadjuvant Treatment ◽  
The Novel ◽  
Newly Diagnosed ◽  
Intravenous Treatment ◽  
Number Of Patients ◽  
Significant Difference ◽  
Novel Coronavirus

<b><i>Background:</i></b> The novel coronavirus disease 2019 has become a worldwide threat. We aimed to explore reflections of these unexpected changes to newly diagnosed cancer patients. <b><i>Method:</i></b> We searched the 2 months after the index case of our country. The first admission day and the first day of intravenous treatment of newly diagnosed patients were recorded. <b><i>Results:</i></b> In the 60 days measured during the pandemic, the total number of patients on polyclinics was 159/weekdays, and the total applied chemotherapy cycles were 276/week. For comparison, the total numbers in the previous year were 267/weekday and 363/week for polyclinic and applied chemotherapy cycles, respectively. The total number of newly admitted patients in 2020 was 283. For comparison, the number of new patients in the same 60-day period in 2019 was 495. Patients who were admitted for adjuvant treatment required a median of 8 days for the first course, those who were admitted for neoadjuvant treatment required 12 days, and metastatic patients required 14 days; there were no significant differences between treatment types (<i>p</i> = 0.233). However, the median treatment time was 11.5 and 17 days, in 2020 and in 2019, respectively. A significant difference was observed between the 2 groups (<i>p</i> &#x3c; 0.001). <b><i>Conclusion:</i></b> The effective shift of workers and accurate regulations have not resulted in apparent delays in patient care. While a decrease in the number of patients has detected, faster healthcare service was introduced to newly diagnosed patients. The reason for the decrease in the number of patients should be investigated with new studies.

Sign in / Sign up

Export Citation Format

Share Document